Cargando…
MUC1 Specific Immune Responses Enhanced by Coadministration of Liposomal DDA/MPLA and Lipoglycopeptide
Mucin 1 (MUC1), a well-known tumor-associated antigen and attractive target for tumor immunotherapy, is overexpressed in most human epithelial adenomas with aberrant glycosylation. However, its low immunogenicity impedes the development of MUC1-targeted antitumor vaccines. In this study, we investig...
Autores principales: | Du, Jing-Jing, Zhou, Shi-Hao, Cheng, Zi-Ru, Xu, Wen-Bo, Zhang, Ru-Yan, Wang, Long-Sheng, Guo, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854779/ https://www.ncbi.nlm.nih.gov/pubmed/35186882 http://dx.doi.org/10.3389/fchem.2022.814880 |
Ejemplares similares
-
Formulation in DDA-MPLA-TDB Liposome Enhances the Immunogenicity and Protective Efficacy of a DNA Vaccine against Mycobacterium tuberculosis Infection
por: Tian, Maopeng, et al.
Publicado: (2018) -
Enhancing immunogenicity of novel multistage subunit vaccine of Mycobacterium tuberculosis using PLGA:DDA hybrid nanoparticles and MPLA: Subcutaneous administration
por: Khademi, Farzad, et al.
Publicado: (2019) -
Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans
por: Katinger, D, et al.
Publicado: (2012) -
Specific Inhibition of VanZ-Mediated Resistance to Lipoglycopeptide Antibiotics
por: Sur, Vishma Pratap, et al.
Publicado: (2021) -
Telavancin: A novel lipoglycopeptide antibiotic
por: Damodaran, S. E., et al.
Publicado: (2011)